R&D News | pharmaphorum

News

Study backs earlier use of Keytruda in cervical cancer

A phase 3 trial of Merck & Co’s checkpoint inhibitor Keytruda could support the expansion of its use in cervical cancer to include newly-diagnosed patients with less s

News

London’s life sciences skyscraper gets planning consent

Plans for a major life sciences development at Canary Wharf in London, UK, have been approved by the local authorities, allowing the project to go ahead.

News

Hearing aids could cut cognitive decline in some patients

With so much attention focused on the use of pricey amyloid-busting therapies for A

News

Pieris wields axe after losing AZ as partner for elarekibep

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strateg

News

Paul Biondi of Flagship's Pioneering Medicines

Pfizer inks $7bn strategic level R&D deal with Flagship

Pfizer has just made venture capital firm Flagship Pioneering a key component of its R&D engine, signing a deal worth up to $7 billion that will allow it to harvest ne

News

BridgeBio rebounds on ATTR cardiomyopathy data

BridgeBio is getting ready to file for FDA approval of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy, armed with positive results in a phase 3 tr

Study backs earlier use of Keytruda in cervical cancer

London’s life sciences skyscraper gets planning consent

Hearing aids could cut cognitive decline in some patients

Pieris wields axe after losing AZ as partner for elarekibep

Pfizer inks $7bn strategic level R&D deal with Flagship

BridgeBio rebounds on ATTR cardiomyopathy data

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks